Surgaflex®
Clinically Proven
In a Prospective Clinical Case Series published in the October 2021 edition of WOUNDS journal, 22 diabetic patients undergoing various surgical procedures were evaluated.
Inclusion Criteria: Diabetic patients – a 13% historical SSI rate. The study’s primary objective was to decrease this rate to 6.5% by prophylactic treatment using Surgaflex™
Procedure: Surgical procedures included amputation, removal of exostosis, midfoot bone removal, Achilles’ tendon repair, bunionectomy, or an elevating osteotomy with primary closure of the wound. Patients were assessed on day 3 or 5 for SSI incidence and followed for 90 days.
Results: The per-protocol patient population (20/22) had a 0% SSI rate with healing times typical to the procedure (between 10 and 34 days). Two patients were not included in the analysis due to non-compliance.9

Get in Touch
HCP Information Request
Complete this form to receive more information about Imbed Biosciences’ products.
Distributor Information Request
Complete this form to receive information about representing Imbed Biosciences products in your accounts.